GeneDx Holdings Corp. (NASDAQ:WGS - Get Free Report)'s stock price hit a new 52-week high during trading on Tuesday . The stock traded as high as $127.55 and last traded at $125.82, with a volume of 33430 shares trading hands. The stock had previously closed at $125.90.
Wall Street Analyst Weigh In
A number of equities analysts have commented on the stock. Piper Sandler set a $120.00 price target on shares of GeneDx and gave the stock an "overweight" rating in a research note on Monday, August 4th. Wall Street Zen raised shares of GeneDx from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd. Wells Fargo & Company lifted their price objective on shares of GeneDx from $78.00 to $95.00 and gave the stock an "equal weight" rating in a report on Wednesday, July 30th. Jefferies Financial Group raised shares of GeneDx from a "hold" rating to a "buy" rating and set a $80.00 price objective for the company in a report on Friday, May 9th. Finally, Guggenheim reaffirmed a "buy" rating and set a $115.00 price objective (up from $88.00) on shares of GeneDx in a report on Monday, June 30th. Six analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $101.63.
View Our Latest Stock Report on WGS
GeneDx Stock Up 6.6%
The company has a market cap of $3.70 billion, a PE ratio of 2,573.20 and a beta of 2.02. The stock's 50 day moving average price is $93.85 and its 200-day moving average price is $87.35. The company has a debt-to-equity ratio of 0.19, a quick ratio of 2.70 and a current ratio of 2.87.
GeneDx (NASDAQ:WGS - Get Free Report) last announced its quarterly earnings data on Tuesday, July 29th. The company reported $0.50 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.10 by $0.40. GeneDx had a net margin of 0.39% and a return on equity of 16.51%. The company had revenue of $102.69 million during the quarter, compared to analysts' expectations of $86.00 million. GeneDx has set its FY 2025 guidance at EPS. On average, analysts predict that GeneDx Holdings Corp. will post 0.97 earnings per share for the current year.
Insider Activity
In other news, CFO Kevin Feeley sold 388 shares of the company's stock in a transaction on Tuesday, July 29th. The shares were sold at an average price of $105.31, for a total value of $40,860.28. Following the completion of the sale, the chief financial officer owned 3,757 shares of the company's stock, valued at approximately $395,649.67. This represents a 9.36% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Casdin Capital, Llc sold 500,000 shares of the company's stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $120.90, for a total transaction of $60,450,000.00. Following the completion of the sale, the director directly owned 3,007,164 shares of the company's stock, valued at $363,566,127.60. This trade represents a 14.26% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 522,411 shares of company stock valued at $62,535,051. Corporate insiders own 29.60% of the company's stock.
Institutional Investors Weigh In On GeneDx
Several institutional investors have recently added to or reduced their stakes in WGS. Sterling Capital Management LLC boosted its position in GeneDx by 877.8% during the 4th quarter. Sterling Capital Management LLC now owns 352 shares of the company's stock valued at $27,000 after buying an additional 316 shares during the period. Lazard Asset Management LLC purchased a new stake in GeneDx during the 4th quarter valued at $35,000. GAMMA Investing LLC boosted its position in GeneDx by 151.7% during the 1st quarter. GAMMA Investing LLC now owns 438 shares of the company's stock valued at $39,000 after buying an additional 264 shares during the period. Comerica Bank purchased a new stake in GeneDx during the 4th quarter valued at $50,000. Finally, US Bancorp DE lifted its position in shares of GeneDx by 3,223.5% in the 1st quarter. US Bancorp DE now owns 565 shares of the company's stock worth $50,000 after purchasing an additional 548 shares during the period. Hedge funds and other institutional investors own 61.72% of the company's stock.
About GeneDx
(
Get Free Report)
GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.
Read More
Before you consider GeneDx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GeneDx wasn't on the list.
While GeneDx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access